Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 7—July 2013
Research

Pneumococcal Serotypes before and after Introduction of Conjugate Vaccines, United States, 1999–20111

Sandra S. RichterComments to Author , Kristopher P. Heilmann, Cassie L. Dohrn, Fathollah Riahi, Daniel J. Diekema, and Gary V. Doern
Author affiliations: Cleveland Clinic, Cleveland, Ohio, USA (S.S. Richter); University of Iowa Carver College of Medicine, Iowa City, Iowa, USA (K.P. Heilmann, C.L. Dohrn, F. Riahi, D.J. Diekema, G.V. Doern)

Main Article

Table 5

Serotype distribution of pneumococcal noninvasive and invasive isolates from children ≤5 y of age, United States, 1999–2011*

Serotype Noninvasive
 Invasive
Before PCV7, 1999–2000 Post-PCV7, 2004–2005 Post-PCV7, 2008–2009 Post-PCV13, 2010–2011 Pen NS, 2010–2011 Before PCV7, 1999–2000 Post-PCV7, 2004–2005 Post-PCV7, 2008–2009 Post-PCV13, 2010–2011 Pen NS, 2010–2011
PCV7
4† 4 (1.3) 0 0 0 0 10 (7.0) 0 0 0 0
6B† 46 (15.1) 5 (1.8) 0 0 0 27 (19.0) 2 (3.8) 0 0 0
9V† 14 (4.6) 1 (0.4) 0 0 0 5 (3.5) 2 (3.8) 0 0 0
14† 28 (9.2) 0 1 (0.3) 0 0 39 (27.5) 0 0 0 0
18C† 7 (2.3) 0 0 0 0 16 (11.3) 0 0 0 0
19F† 53 (17.4) 19 (6.9) 14 (3.8) 7 (2.2) 6 (3.2) 16 (11.3) 7 (13.2) 1 (2.0) 0 0
23F† 37 (12.1) 8 (2.9) 2 (0.5) 0 0 8 (5.6) 0 0 0 0
Total
 189 (63.0)
 33 (12.0)
 17 (4.6)
 7 (2.2)
 6 (3.2)
121 (85.2)
 11 (20.8)
 1 (2.0)
 0
 0
Additional serotypes in PCV13
1† 2 (0.7) 1 (0.4) 0 0 0 1 (0.7) 1 (1.9) 1 (2.0) 0 0
3† 14 (4.6) 22 (8.0) 14 (3.8) 13 (4.0) 0 0 1 (1.9) 3 (6.1) 2 (4.9) 0
5† 0 0 0 0 0 0 0 1 (2.0) 0 0
6A 24 (7.9) 16 (5.8) 5 (1.4) 1 (0.3) 1 (0.5) 11 (7.8) 3 (5.7) 0 0 0
7F† 1 (0.3) 2 (0.7) 6 (1.6) 2 (0.6) 0 1 (0.7) 0 8 (16.3) 2 (4.9) 0
19A† 11 (3.6) 68 (24.7) 135 (36.7) 107 (32.8) 94 (50.3) 1 (0.7) 15 (28.3) 18 (36.7) 18 (43.9) 13 (59.1)
Total
 52 (17.3)
 109 (39.6)
 160 (43.5)
 123 (37.7)
 95 (50.8)
14 (9.9)
 20 (37.7)
 31 (63.3)
 22 (53.7)
 13 (59.1)
PCV-related
6C 2 (0.7) 2 (0.7) 28 (7.6) 29 (8.9) 21 (11.2) 0 0 1 (2.0) 3 (7.3) 2 (9.1)
9N 4 (1.3) 1 (0.4) 2 (0.5) 2 (0.6) 0 0 0 0 0 0
23A 0 8 (2.9) 17 (4.6) 10 (3.1) 5 (2.7) 0 1 (1.9) 1 (2.0) 0 0
23B 0 4 (1.5) 14 (3.8) 9 (2.8) 1 (0.5) 0 0 0 2 (4.9) 2 (9.1)
Other 4 (1.3)‡ 3 (1.1)§ 5 (1.4)¶ 1 (0.3)# 0 1 (0.7)‡ 1 (1.9)§ 0 0 0
Total
 10 (3.3)
 18 (6.5)
 66 (17.9)
 51 (15.6)
 27 (14.4)
1 (0.7)
 2 (3.8)
 2 (4.1)
 5 (12.2)
 4 (18.2)
Non-PCV
11A† 3 (1.0) 15 (5.5) 12 (3.3) 14 (4.3) 4 (2.1) 0 1 (1.9) 0 0 0
15A 3 (1.0) 9 (3.3) 13 (3.5) 2 (0.6) 0 0 1 (1.9) 3 (6.1) 1 (2.4) 1 (4.5)
15B† 3 (1.0) 10 (3.6) 14 (3.8) 20 (6.1) 11 (5.9) 1 (0.7) 2 (3.8) 0 2 (4.9) 0
15C 2 (0.7) 7 (2.6) 11 (3.0) 14 (4.3) 7 (3.7) 1 (0.7) 2 (3.8) 2 (4.1) 3 (7.3) 1 (4.5)
21 3 (1.0) 1 (0.4) 9 (2.5) 9 (2.8) 2 (1.1) 0 0 0 0 0
22F† 2 (0.7) 12 (4.4) 7 (1.9) 18 (5.5) 0 1 (0.7) 2 (3.8) 3 (6.1) 2 (4.9) 0
35B
 6 (2.0)
 23 (8.4)
 20 (5.4)
 36 (11.0)
 35 (18.7)
0
 1 (1.9)
 0
 3 (7.3)
 3 (13.6)
Other
 15 (5.0)**
 36 (13.1)††
 35 (9.5)‡‡
 26 (8.0)§§
 0
2 (1.4)**
 11 (20.8)††
 7 (14.3)‡‡
 3 (7.3)§§
 0
NT
 12 (3.9)
 2 (0.7)
 4 (1.1)
 6 (1.8)
 0
1 (0.7)
 0
 0
 0
 0
Total
 49 (16.3)
 115 (41.8)
 125 (34.0)
 145 (44.5)
 59 (31.6)
6 (4.2)
 20 (37.7)
 15 (30.6)
 14 (34.1)
 5 (22.7)
All
 300
 275
 368
 326
 187
142
 53
 49
 41
 22
% Pen NS 50.2 48.0 59.2 57.4 NA 26.1 43.4 40.8 53.7 NA

*Values are no. (%) isolates unless otherwise indicate. PCV7, pneumococcal conjugate 7-valent vaccine; PCV13, pneumococcal conjugate 13-valent vaccine; Pen NS, penicillin nonsusceptible (MIC ≥0.12 µg/mL); NT, nontypeable; NA, not applicable; non, noninvasive; inv, invasive.
†Serotypes in 23-valent polysaccharide pneumococcal vaccine.
‡Other low prevalence serotypes (no. isolates): in 1999–00, serotype 9A (1 non; 1 inv), 18B (3 non).
§In 2004–2005, serotype 9A (1 non), 18A (1 non), 18B (1 non), 19B (1 inv).
¶In 2008–2009, serotype 7C (5 non).
#In 2010–11, serotype 7B (1 non).
**In 1999–2000, serotype 10A (3 non), 12F (1 inv), 13 (1 non), 16A (1 non), 17F (1non), 25A (2 non, 1 inv), 29 (1 non), 33F (2 non), 33A (1 non), 35F (2 non), 45 (1 non).
††In 2004–2005, serotype 10A (1 non), 12F (1 non, 1 inv), 16F (3 non, 2 inv), 16A (1 non), 20 (1 non, 1 inv), 25A (1 inv), 29 (6 non), 31 (5 non, 1 inv), 33F (4 non), 33A (1 non, 2 inv), 34 (1 non), 35F (5 non, 1 inv), 35A (4 non), 38 (1 non, 2 inv), 39 (1 non), 48 (1 non).
‡‡In 2008–2009, serotype 8 (1 non), 10A (4 non), 12F (1 inv), 16F (5 non), 17F (4 non, 2 inv), 20 (1 non), 22A (1 non), 25A (1 non), 29 (1 non, 1 inv), 31 (2 non), 33F (2 non), 33A (2 non, 1 inv), 33B (1 non), 34 (3 non, 1 inv), 35F (5 non, 1 inv), 35C (1 non), 42 (1 non).
§§In 2010–2011, serotype 10A (5 non), 16F (5 non), 17F (3 non), 24A (1 non), 31 (2 non), 33F (2 non, 1 inv), 33A (1 non, 2 inv), 34 (2 non), 35F (4 non), 45 (1 non).

Main Article

1Presented in part at the 112th General Meeting of the American Society for Microbiology Annual Meeting, June 19, 2012, San Francisco, CA, USA (abstract no. 2986).

Page created: June 17, 2013
Page updated: June 17, 2013
Page reviewed: June 17, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external